ArticleVirology journal2026
Metabolic associated fatty liver disease induced hepatocyte apoptosis to eliminate hepatitis B virus.
Article in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
BACKGROUD AND
aimWith the rising prevalence of chronic hepatitis B (CHB) co-occurring with metabolic dysfunction-associated fatty liver disease (MAFLD), an in-depth investigation into the impact and mechanisms of MAFLD on CHB is urgently needed. Prior studies have reported that patients with concomitant CHB and MAFLD exhibit lower levels of hepatitis B virus (HBV) replication; however, the underlying mechanistic basis remains unclear. Accumulating evidence indicates that induction of apoptosis is a critical mechanism for HBV clearance. Therefore, it remains to be determined whether lipotoxicity-induced hepatocyte apoptosis contributes significantly to the accelerated elimination of HBV. To investigate the effects and underlying mechanisms of fatty acids against HBV in HepG2.2.15 cells.
methodsHuman liver transcriptome data were used to analyze biological changes in CHB patients with MAFLD compared to those with CHB alone. In vitro, palmitic acid (PA) was used to simulate lipotoxicity in HepG2.2.15 cells, and oleic acid (OA) was used to reverse the effects of PA. The levels of HBsAg, HBeAg, and HBV-DNA in cell supernatants and lysates were detected by ELISA and PCR. Mitochondrial membrane permeability, oxidative stress, and apoptosis were evaluated to investigate the potential mechanisms of PA's effects on HepG2.2.15 cells.
resultsHuman hepatic transcriptome enrichment analysis showed upregulated apoptosis-related pathways and downregulated mitochondrial/redox genes in patients with comorbid CHB and MASH. Cell experiments showed that PA reduced the levels of HBsAg, HBeAg, and HBV-DNA in HepG2.2.15 cell supernatants and lysates. The underlying mechanism is that PA increased mitochondrial membrane permeability and ROS levels to activate Caspase-9, PARP, and Caspase-3, thereby inducing apoptosis. However, the unsaturated fatty acid OA restored mitochondrial function, reduced oxidative stress and apoptosis, and reversed HBV antigen levels.
conclusionPA activates the mitochondrial apoptotic pathway to promote HBV clearance, while OA can reverse this effect. This study provides new evidence for the interaction mechanism between CHB and MAFLD and suggests new treatment strategies for patients with this comorbidity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.